As shown in Fig. 3, elevated KPNA2 mRNA expression across all breast cancer types was associated with poorer OS (HR 1.68, CI 95% 1.35–2.08-, P = 2.6E-6, Fig. 3A), RFS (HR 1.58, CI 95% 1.42–1.76, P < 1E-16, Fig. 3B), DMFS (HR 1.73, CI 95% 1.42–2.1, P = 3.9E-8, Fig. 3C) and had no statistically significant impact on PPS (HR 1.71, CI 95% 1.32–2.22, P = 3.8E-5, Fig. 3D). This evidence concerns the gene KPNA2 and breast carcinoma.